Global Anticoagulants Market Report and Forecast 2024-2032

Global Anticoagulants Market Outlook

The global anticoagulants market size attained a value of USD 37.65 billion in 2023 driven by growing lifestyle risks like diabetes and obesity, along with the growing health awareness among the public, currently require better and efficient treatments. The market is anticipated to grow at a CAGR of 8.2% during the forecast period of 2024-2032 to attain a value of USD 76.53 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

North America has a Significant Market Share in the Anticoagulants Industry

North America is one of the major markets in the anticoagulants industry. This can be attributed to the increase in the incidence rate of cardiovascular diseases in North America. According to Centres for Disease Control and Prevention, one in every 4 deaths is caused by heart disease, i.e., about 655,000 Americans die from heart disease each year. Further, a well-established healthcare infrastructure, along with the presence of key pharma and biotech companies, is supporting the entire regional market's expansion to a great extent.

Rising Cases of Cardiovascular Diseases in Europe and the Asia Pacific to Augment the Market Growth

Europe is also a significant contributor to the anticoagulants industry. According to the European Society of Cardiology (ESC), the region witnesses more than 11 million new cases of cardiovascular diseases (CVD) on the whole every year, as per 2019 statistics. In the EU, about 49 million people are currently living with this condition. Further, as per ESC, CVD is the leading cause of death in Europe, accounting for about 45% of all deaths and 37% in the EU. Meanwhile, major countries in the Asia Pacific, such as China, are also rising cases of CVD. China is witnessing an increasing mortality rate attributed to CVD. In 2016, as reported by the Journal of Geriatric Cardiology, cardiovascular disease (CVD) was the top cause of mortality in both rural and urban areas, accounting for 45.50% and 43.16% of all deaths, respectively. This is likely to make China an emerging market for anticoagulants in the forecast period.

Anticoagulants: Market Segmentation

Anticoagulants are referred to as those drugs that prevent the formation of blood clots. They're given to those who have a high risk of blood clots to help them avoid catastrophic diseases, including strokes and heart attacks. Anticoagulants act by inhibiting the process that causes the formation of blood clots. They are also known as "blood thinners".

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

On the basis of drug class, the market can be classified into:

• Novel Oral Anticoagulants (NOACs)
• Heparin and Low Molecular Weight Heparin (LMWH)
• Vitamin K Antagonist

The market can be broadly categorised on the basis of its applications into:

• Atrial Fibrillation/Myocardial Infarction (Heart Attack)
• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism
• Others

The EMR report looks into the regional markets of anticoagulants like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Rising Lifestyle Risks Like Obesity and Diabetes to Boost the Anticoagulants Industry

The growing lifestyle risks like diabetes and obesity, along with the growing health awareness among the public, currently require better and efficient treatments. The introduction of NOACs has resulted in a significant increase in anticoagulant use and expenditure. The development of pharmaceuticals and therapeutic companies is boosting the production and efficiency of anticoagulants. This is augmenting the market growth of anticoagulants. The risks and threats for health posed by COVID-19 have boosted investments in the anticoagulant industry. The growing healthcare expenditure by the government, along with key market players, is a huge driving force for the market. There are strict government regulations attributed to the safety and dosage of anticoagulants. The FDA approval of anticoagulants usage for paediatric heart patients in 2019 is also a huge boost to the industry.

Key Industry Players in the Global Anticoagulants Market

The report presents a detailed analysis of the following key players in the global anticoagulants market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• Johnson & Johnson Services, Inc.
• Bayer AG 
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company, Limited
• GlaxoSmithKline plc
• Aspen Pharmacare Holdings Limited
• Pfizer Inc.
• Portola Pharmaceuticals, Inc.
• Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report

Anticoagulants Market Report Snapshots

Anticoagulants Market Size

Anticoagulants Market Growth

Anticoagulants Companies